Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed Papers

Cutaneous and pulmonary sarcoidosis following treatment of multiple sclerosis with interferon-beta-1b: a case report.
The extent of ultrastructural spinal cord pathology reflects disease severity in experimental autoimmune encephalomyelitis.
LINGO-1 is a component of the Nogo-66 receptor/p75 signaling complex.
Lenalidomide, Dexamethasone and MEDI-551 in Untreated Multiple Myeloma
Ultrasound aspects in therapy-naive CIDP compared to long-term treated CIDP.
Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Transcriptional response to interferon beta-1a treatment in patients with secondary progressive multiple sclerosis.
Mapi Pharma Receives Additional Claims for Its U.S. Patent for Glatiramer Acetate Depot for the Treatment of Multiple Sclerosis
Anti-Epstein-Barr virus antibodies as serological markers of multiple sclerosis: a prospective study among United States military personnel.
Cranial neuropathies in multiple sclerosis defined by magnetic resonance imaging and fludeoxyglucose f 18 positron emission tomography.
Calpain inhibition attenuated morphological and molecular changes in skeletal muscle of experimental allergic encephalomyelitis rats.
Clinical and immunological follow-up of B-cell depleting therapy in CNS demyelinating diseases.
A comparative study of experimental mouse models of central nervous system demyelination.
Tumefactive Demyelinating Lesions in Multiple Sclerosis and Associated Disorders.
Genzyme’s Lemtrada™ approved in Australia for treatment of multiple sclerosis
It is better to be in a clinical trial than not: lessons learnt from clinical neurology--the management of acute multiple sclerosis relapses.
Acorda Therapeutics announces top line results of post-marketing commitment study exploring 5 mg dose of dalfampridine-ER
Multiple sclerosis.
The effect of the interval-between-sessions on prefrontal transcranial direct current stimulation (tDCS) on cognitive outcomes: a systematic review and meta-analysis.
Efficacy and safety of interferon beta-1b sc in older RRMS patients--a posthoc analysis of the BEYOND study.
Dopaminergic Modulation of CD4+CD25 Regulatory T Lymphocytes in Multiple Sclerosis Patients during Interferon-β Therapy.
Receptos Reports Positive Phase 2 Results for RPC1063 in Relapsing Multiple Sclerosis
Rituximab: Don't Count It Out as MS Treatment
Benefit of additional screening for progressive multifocal leukoencephalopathy in patients with multiple sclerosis taking natalizumab: a decision analysis.
Immunoglobulin M oligoclonal bands: biomarker of targetable inflammation in primary progressive multiple sclerosis.

Pages